Structure-Activity Relationship and Biological Investigation of SR18292 (16), a Suppressor of Glucagon-Induced Glucose Production.
Structure-Activity Relationship and Biological Investigation of SR18292 (16), a Suppressor of Glucagon-Induced Glucose Production.
复制标题
DOI:
10.1021/acs.jmedchem.0c01450
复制
发表时间:
2021-01-28
影响因子:
7.3
通讯作者:
Kamenecka TM
中科院分区:
文献类型:
--
作者:
Lin H;Sharabi K;Lin L;Ruiz C;Zhu D;Cameron MD;Novick SJ;Griffin PR;Puigserver P;Kamenecka TM
Despite a myriad of available pharmacotherapies for the treatment of Type-2 diabetes (T2D), challenges still exist in achieving glycemic control. Several novel glucose-lowering strategies are currently under clinical investigation highlighting the need for more robust treatments. Previously, we have shown that suppressing PGC1α activity with a small molecule (SR18292, 16) can reduce glucose release from hepatocytes and ameliorate hyperglycemia in diabetic mouse models. Despite structural similarities in 16 to known β-blockers, detailed SAR studies described herein have led to the identification of analogs lacking β-adrenergic activity that still maintain the ability to suppress glucagon-induced glucose release from hepatocytes and ameliorate hyperglycemia in diabetic mouse models. Hence, these compounds exert their biological effects in a mechanism that does not include adrenergic signaling. These probe molecules may lead to a new therapeutic approach to treat T2D either as a single agent or in combination therapy.
登录
查看更多内容
影响因子:
29
作者:
Lin HV;Accili D
通讯作者:
Accili D
影响因子:
64.8
作者:
Rodgers, JT;Lerin, C;Puigserver, P
通讯作者:
Puigserver, P
影响因子:
16
作者:
Dominy, John E., Jr.;Lee, Yoonjin;Jedrychowski, Mark P.;Chim, Helen;Jurczak, Michael J.;Camporez, Joao Paulo;Ruan, Hai-Bin;Feldman, Jessica;Pierce, Kerry;Mostoslavsky, Raul;Denu, John M.;Clish, Clary B.;Yang, Xiaoyong;Shulman, Gerald I.;Gygi, Steven P.;Puigserver, Pere
通讯作者:
Puigserver, Pere
影响因子:
64.8
作者:
通讯作者:
--
影响因子:
10.6
作者:
Sharabi K;Tavares CD;Rines AK;Puigserver P
通讯作者:
Puigserver P